Tivozanib US FDA Label
- Compound: 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
- Description: Tivozanib is a member of the class of quinolines that is 6,7-dimethoxyquinoline substituted by a 3-chloro-4-{[(5-methyl-1,2-oxazol-3-yl)carbamoyl]amino}phenoxy group at position 4. It is a potent and selective inhibitor of VEGF receptor tyrosine kinases and was previously in clinical development for the treatment of metastatic renal cell carcinoma. It has a role as a vascular endothelial growth factor receptor antagonist, an antineoplastic agent and an apoptosis inducer. It is an aromatic ether, a member of isoxazoles, a member of phenylureas, a member of monochlorobenzenes and a member of quinolines.
- Brand Name:
- Code(s): AV951
- Approved:
- Kinase Class: RY
- Inhibitor Type: IIA
- Literature (PubMed): 0
- Target(s): Fms related receptor tyrosine kinase 1 , fms related receptor tyrosine kinase 4 , kinase insert domain receptor , KIT proto-oncogene, receptor tyrosine kinase , Platelet derived growth factor receptor beta
- Disease(s): renal cell carcinoma